Loading, Please Wait...
LAS VEGAS, Nevada, April 15, 2019 (GLOBE NEWSWIRE) -- Praxsyn (OTC:PXYN) is pleased to provide this corporate update to all of our shareholders.
Praxsyn (the, “Company”) has published, unaudited Financial Statements and an Initial Information Statement in the form of an Annual Report for the periods ending December 31, 2018 and 2017 with OTCMarkets.com. That process is complete, and as of April 11, 2019. Praxsyn enjoys Current Status with OTC Markets.com. The Company is now working diligently to complete its Q1 2019 Financial Statements and intends to file them with OTCMarkets.com before the due date on May 15, 2019.
We continue to work to obtain audited financials for the same periods posted and contemplate concluding that process near the end of Q2, 2019. Thereafter, we intend to file a Form 10 in a single presentation, with the SEC as soon as practicable.
The company is taking this two-stage approach in order to (a) get accurate information to shareholders as soon as possible and (b); to allow us to enter into negotiations with our secured and unsecured creditors to settle as much of our debt as possible prior to completing and filing our Form 10.
Negotiations with those creditors are ongoing and we believe are developing in a very positive direction. We hope to announce the first of those settlements in the very near term, possibly as soon as this week.
About Praxsyn Corporation
Headquartered in Las Vegas, Nevada, Praxsyn Corporation works to realize the vision of medical professionals to improve the lives of their patients. Additional company information can be found at www.praxsyncorp.com.
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, the intended outcomes of our trials, the efficacy and safety of our products and therapies, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue Praxsyn's business and product development plans and overall market conditions. These forward-looking statements are made as of the date of this press release, and Praxsyn assumes no obligation to update the forward-looking statements. We may use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this pressrelease will prove to be accurate.